A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir
Julie B. Dumond(University of North Carolina at Chapel Hill), Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Ninh M. La‐Beck(Texas Tech University), Murray Drulak(Boehringer Ingelheim (United States)), Steven H. Jennings(University of North Carolina at Chapel Hill), Thomas R. MacGregor(Boehringer Ingelheim (United States)), Nicole White(University of North Carolina at Chapel Hill), John P. Sabo(Boehringer Ingelheim (Brazil)), Mark Castles(Boehringer Ingelheim (United States)), Nardin Rezk(Jewish General Hospital), Jingbaoyi Li(University of North Carolina at Chapel Hill), Michael J. Wagner(University of North Carolina at Chapel Hill), H.-C. Tien(University of North Carolina at Chapel Hill), Sun Ok Choi(University of North Carolina at Chapel Hill), Kristine B. Patterson(University of North Carolina at Chapel Hill), Manoli Vourvahis(Pfizer (United States))
Cited by 63
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
|The Journal of Infectious Diseases|2016|303
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
|Annals of Internal Medicine|2014|262
Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|193